EZH2 and hematologic disorder: With respect to the latter, that is, GoF EZH2 mutations, relatively recent research provides evidence of that the clinical utility and development of small molecule EZH2 inhibitors provide a means to arrest aberrant leukemic/lymphoid transformation in certain hematological malignancies.